Form 4: Orchestra BioMed Director Exercises Stock Options

Director Jason Aryeh exercised stock options to acquire 11,700 shares of Orchestra BioMed common stock.

Summary

• Jason Aryeh, a director at Orchestra BioMed Holdings, Inc., exercised stock options to purchase 11,700 shares of common stock.
• The transaction occurred on December 27, 2024, at a price of $4.3 per share.
• Following the transaction, Mr. Aryeh directly owns 80,060 shares of common stock.
• The stock options were granted on January 26, 2023, and expire on November 16, 2028.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it reports a standard transaction. The exercise of options by a director can be seen as a positive sign of confidence, but it is not a major event.

Positives

• The exercise of stock options by a director can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US.
• The transaction is typical for directors who are granted stock options as part of their compensation package.
• The exercise of options at a set price is a common mechanism for aligning the interests of management with those of shareholders.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates director confidence.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, Orchestra BioMed, OBIO, director, equity